These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 31061971)

  • 21. Euglycemic Diabetic Ketoacidosis in a Lung Cancer Patient Using Empagliflozin.
    Sexe J; Mayes C; Tofts P
    Case Rep Crit Care; 2020; 2020():7437892. PubMed ID: 32695525
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Commentary: SGLT inhibitors in type 1 diabetes: Place in therapy and a risk mitigation strategy for preventing diabetic ketoacidosis - the STOP DKA protocol.
    Rendell MS
    Diabetes Obes Metab; 2019 Oct; 21(10):2189-2191. PubMed ID: 31334593
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hyperglycemic, high anion-gap metabolic acidosis in patients receiving SGLT-2 inhibitors for diabetes management.
    Kum-Nji JS; Gosmanov AR; Steinberg H; Dagogo-Jack S
    J Diabetes Complications; 2017 Mar; 31(3):611-614. PubMed ID: 27913012
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sodium Glucose Transporter 2 Inhibitors and Diabetic Ketoacidosis in Three Patients with Diabetes: Underlying Causation.
    Kelley JL; Strum M; Riche DM; Chandler AM
    J Pharmacol Pharmacother; 2017; 8(3):137-139. PubMed ID: 29081625
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Euglycemic Diabetic Ketoacidosis in a 27 year-old female patient with type-1-Diabetes treated with sodium-glucose cotransporter-2 (SGLT2) inhibitor Canagliflozin.
    Bader N; Mirza L
    Pak J Med Sci; 2016; 32(3):786-8. PubMed ID: 27375734
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SGLT2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis: A Case Report.
    Wang KM; Isom RT
    Kidney Med; 2020; 2(2):218-221. PubMed ID: 32734242
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.
    Macha S; Mattheus M; Halabi A; Pinnetti S; Woerle HJ; Broedl UC
    Diabetes Obes Metab; 2014 Mar; 16(3):215-22. PubMed ID: 23859488
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sodium-glucose cotransporter-2 inhibition and acidosis in patients with type 2 diabetes: a review of US FDA data and possible conclusions.
    D'Elia JA; Segal AR; Bayliss GP; Weinrauch LA
    Int J Nephrol Renovasc Dis; 2017; 10():153-158. PubMed ID: 28670136
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Canagliflozin-Induced Diabetic Ketoacidosis: Case Report and Review of the Literature.
    Turner J; Begum T; Smalligan RD
    J Investig Med High Impact Case Rep; 2016; 4(3):2324709616663231. PubMed ID: 27635409
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The sodium glucose cotransporter type 2 inhibitor empagliflozin preserves β-cell mass and restores glucose homeostasis in the male zucker diabetic fatty rat.
    Hansen HH; Jelsing J; Hansen CF; Hansen G; Vrang N; Mark M; Klein T; Mayoux E
    J Pharmacol Exp Ther; 2014 Sep; 350(3):657-64. PubMed ID: 24993361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Euglycemic Diabetic Ketoacidosis: A Review.
    Modi A; Agrawal A; Morgan F
    Curr Diabetes Rev; 2017; 13(3):315-321. PubMed ID: 27097605
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic Ketoacidosis.
    Hampp C; Swain RS; Horgan C; Dee E; Qiang Y; Dutcher SK; Petrone A; Chen Tilney R; Maro JC; Panozzo CA
    Diabetes Care; 2020 Jan; 43(1):90-97. PubMed ID: 31601640
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Use of SGLT-2 Inhibitors Coupled With a Strict Low-Carbohydrate Diet: A Set-Up for Inducing Severe Diabetic Ketoacidosis.
    Guirguis H; Beroukhim Afrahimi S; Pham C
    Clin Med Insights Case Rep; 2022; 15():11795476221090045. PubMed ID: 35418794
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of Diabetic Ketoacidosis in Adults: A Narrative Review.
    Eledrisi MS; Elzouki AN
    Saudi J Med Med Sci; 2020; 8(3):165-173. PubMed ID: 32952507
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Population-based incidence of diabetic ketoacidosis in type 2 diabetes: medical claims data analysis in Japan.
    Takeuchi M; Kawamura T; Sato I; Kawakami K
    Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):123-126. PubMed ID: 28752620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population Pharmacokinetic- Pharmacodynamic Analysis to Characterize the Effect of Empagliflozin on Renal Glucose Threshold in Patients With Type 1 Diabetes Mellitus.
    Mondick J; Riggs M; Kaspers S; Soleymanlou N; Marquard J; Nock V
    J Clin Pharmacol; 2018 May; 58(5):640-649. PubMed ID: 29251772
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolic encephalopathy secondary to diabetic ketoacidosis: a case report.
    Tomkins M; McCormack R; O'Connell K; Agha A; Merwick Á
    BMC Endocr Disord; 2019 Jul; 19(1):71. PubMed ID: 31266485
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: An updated review of the literature.
    Bonora BM; Avogaro A; Fadini GP
    Diabetes Obes Metab; 2018 Jan; 20(1):25-33. PubMed ID: 28517913
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Case of Diabetic Ketoacidosis in a Patient on an SGLT2 Inhibitor and a Ketogenic Diet: A Critical Trio Not to Be Missed.
    Steinmetz-Wood S; Gilbert M; Menson K
    Case Rep Endocrinol; 2020; 2020():8832833. PubMed ID: 32855828
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of kidney proximal tubular glucose reabsorption does not prevent against diabetic nephropathy in type 1 diabetic eNOS knockout mice.
    Gangadharan Komala M; Gross S; Mudaliar H; Huang C; Pegg K; Mather A; Shen S; Pollock CA; Panchapakesan U
    PLoS One; 2014; 9(11):e108994. PubMed ID: 25369239
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.